Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enzolytics Inc (OP: ENZC )

0.0009 +0.0001 (+12.50%)
Streaming Delayed Price Updated: 2:40 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enzolytics Inc

< Previous 1 2 3 Next >
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
Via ACCESSWIRE
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials
Via ACCESSWIRE
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
Via ACCESSWIRE
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
Via ACCESSWIRE
Stock Market Surges “Milestones Reached”: SWISF / SKUR.C, NWBO, ENZC, ABML
Via AB Newswire
Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 Project
Via ACCESSWIRE
Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review
Via ACCESSWIRE
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies
Via ACCESSWIRE
Enzolytics, Inc. Highlights Plans for Promotion of IPF Immune(TM), Its Patented Nutraceutical Supplement
Via ACCESSWIRE
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023
Via ACCESSWIRE
Undervalued Biotech Stocks to Watch After Enzolytics’ (OTC:ENZC) 300% Run: RMED, SPPI, HALB, VXRT
Via AB Newswire
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
Via ACCESSWIRE
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success
Via ACCESSWIRE
Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics
Via ACCESSWIRE
Enzolytics to Develop Feline Monoclonal Antibodies
Via ACCESSWIRE
Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials
Via ACCESSWIRE
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
Via ACCESSWIRE
Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project
Via ACCESSWIRE
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa
Via ACCESSWIRE
Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV
Via ACCESSWIRE
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune(TM)
Via ACCESSWIRE
Enzolytics, Inc. Announces New Advisory Board Member
Via ACCESSWIRE
Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
Via ACCESSWIRE
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies
Via ACCESSWIRE
Enzolytics Inc. Announces Litigation Success, Accounting Progress and Removal of "Yield" Sign on OTC Markets Stock Quotes
Via ACCESSWIRE
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering... 
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
Via ACCESSWIRE
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
COLLEGE STATION, TX / ACCESSWIRE / June 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (ENZC" or the "Company") today announced it has identified conserved, immutable sites (epitopes) on the Monkeypox... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug... 
Via Newsfile
Exposures COVID-19
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans
This version includes the Safe Harbor statement that was missing from the previous version of this release. COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC)... 
From Enzolytics, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.